What are the opening hours?

Monday 9am - 5pm Tuesday 9am - 5pm Wednesday 9am - 5pm Thursday 9am - 5pm Friday 9am - 5pm

Perspectum

Home
United Kingdom
Oxford
Perspectum

Innovating medical imaging in Oxford - where tradition meets technology. AI-driven, patient-focused, advancing healthcare.

Perspectum is a medical diagnostics company, and developer of LiverMultiScan, a non-invasive MRI based test for liver disease. Follow the link to our website to discover more about advanced liver visualisation

We hope to use this page to keep in touch with people interested in us, as well as the wider liver community.

30/04/2026

MRCP+ is a non-invasive, quantitative MRI solution providing accurate 3D visualisation alongside precise quantitative assessment of the biliary tree and pancreatic duct, supporting physicians in the diagnosis and monitoring of pancreatobiliary disease.

Designed to support clinical decision-making, MRCP+ offers:

• Safe and non-invasive assessment
A quick, non-contrast MRI scan that enables comprehensive evaluation of the biliary system without invasive procedures

• Early identification
Quantitative metrics that support detection of biliary abnormalities, including strictures and dilatations, at an earlier stage

• Reliable monitoring
Enables longitudinal assessment with reproducible, repeatable measurements to track disease progression and response to intervention

• Prognostic insight
Objective ductal metrics that support risk assessment and inform management decisions

• Patient-friendly reporting
Clear, structured reports with enhanced 3D visualisations to improve clinical communication and patient understanding

Monitoring meaningful change in biliary disease can be complex. By providing quantitative metrics such as biliary tree volume, duct counts, stricture and dilatation assessment, and maximum common bile duct diameter, MRCP+ delivers objective data to complement visual interpretation and support confident decision-making.

Explore MRCP+ further and request a demo:
https://www.perspectum.com/our-products/mrcp

28/04/2026

At American Association of Clinical Endocrinology 2026, one message came through clearly: metabolic care is moving earlier.

For many endocrinologists, the challenge isn’t just managing MASLD, it’s identifying risk before patients progress.

Across conversations, there was growing alignment around a more proactive approach:
non-invasive, quantitative tools that can detect, stratify, and monitor disease earlier in the pathway.

MRI-derived biomarkers such as cT1 and PDFF are increasingly being used to support:
• earlier identification of patients at risk
• more confident risk stratification
• longitudinal monitoring of clinically meaningful change

This is more than an imaging trend. It reflects a shift toward data-driven, preventative care, especially important as MASLD remains underdiagnosed despite its high prevalence and links to metabolic disease.

At Perspectum, we’re focused on enabling this transition with quantitative MRI solutions designed to integrate into clinical workflows and support better-informed decisions over time.

If we didn’t connect at AACE and you’re exploring how quantitative MRI could support your clinical practice or research:

Learn more: https://perspectum.com/
Connect with our team: https://t8glx.share.hsforms.com/2pZ-uQnvBQ562gUAkYToz9Q

22/04/2026

Live from American Association of Clinical Endocrinology 2026

Great to be on the ground connecting with clinicians and partners across the endocrinology community, discussing how the understanding of metabolic disease continues to evolve.

At this year, we’re sharing new data on:

• Multi-organ inflammation in type 2 diabetes
• Imaging-driven risk stratification in obesity
• Scalable body composition assessment linked to clinical outcomes

If you’re attending, come and speak with the team at Booth #417 to learn more about how imaging biomarkers are supporting a more complete, quantitative assessment of metabolic health.

21/04/2026

Obesity-related HFpEF is commonly viewed through a cardiac lens. But could expanding that view improve how we understand and manage the condition?

Our latest review explores the condition as a multiorgan, cardio–renal–hepatic–metabolic (CRHM) syndrome, where obesity related HFpEF is promoted through metabolic dysfunction, systemic inflammation and ectopic adiposity among other factors.

By bringing together emerging evidence on incretin-based therapies and advanced imaging endpoints, the paper highlights a shift:

🔵 From single-organ thinking to integrated, system-level understanding
🔵 From indirect markers to imaging-based insights into organ health
🔵 From static assessment to tracking disease across organs over time

This perspective matters. Cardiometabolic disease does not develop in isolation, and neither should the tools we use to understand and monitor it.

Read the full paper: https://link.springer.com/article/10.1007/s10741-026-10629-z

19/04/2026

Solid Habits, Strong Liver.

This World Liver Day focuses on the everyday choices that support liver health, nutrition, movement, and routine checks.

But there is a challenge.

Liver disease often develops silently, with many people feeling well until it has progressed.

Habits matter. Understanding the impact of you habits is what makes change possible

LiverMultiScan provides non-invasive insight into liver health, helping to:

Quantify liver fat, disease activity, and iron
Identify signs of liver disease before symptoms appear
Monitor changes over time
Because strenghting your liver health is not just about what you do, it’s about what you can see and track.

This World Liver Day, consider not only the habits that support liver health, but how you understand their impact.

Learn more: https://perspectum.com/

15/04/2026

As our understanding of MASLD continues to evolve, so does the role of non-invasive diagnostics in clinical practice.

Imaging-based biomarkers are increasingly being explored for their ability to provide additional insight beyond fibrosis alone, particularly in the assessment of liver tissue biology and disease activity.

Recent clinical care pathways have begun to acknowledge MRI-based biomarkers such as cT1 in specialty settings, reflecting growing interest in their potential role alongside established tools.

At American Association of Clinical Endocrinology, discussions continue to reflect a shift toward quantitative, non-invasive approaches in MASLD management, alongside established pathways.

Looking ahead to , the focus remains on how imaging biomarkers can complement current tools to support earlier identification, more refined risk stratification, and improved monitoring of disease over time.

Evidence snapshot: Banerjee et al., J Hepatol 2014; Mojtahed et al., Abdom Radiol 2019; Andersson et al., CGH 2022; Gu et al., Eur J Clin Invest 2021

14/04/2026

In primary sclerosing cholangitis (PSC), assessing periductal disease activity remains a significant challenge.

We’re pleased to share new research introducing periductal cT1 (Pd-cT1) — a novel multiparametric MRI/MRCP approach designed to quantify fibro-inflammatory changes surrounding the bile ducts.

In patients with large-duct PSC, Pd-cT1:

Detected periductal abnormalities

Showed associations with established risk markers

Was associated with subsequent adverse clinical outcomes

These findings support the potential of Pd-cT1 as an objective, non-invasive imaging biomarker of periductal disease activity in PSC.

By enabling the assessment of disease activity, Pd-cT1 may help inform clinical trial design and reduce reliance on invasive procedures in PSC research settings.

📄 Read the paper: https://link.springer.com/article/10.1186/s12880-026-02242-1

09/04/2026

Metabolic disease is often managed without a clear view of liver health.
Yet MASLD is highly prevalent in patients with type 2 diabetes, and frequently underdiagnosed.

At AACE 2026, we’re joining the endocrinology community to explore how noninvasive, quantitative imaging can help uncover hidden liver risk, support earlier identification, and enable more informed monitoring over time.

Technologies like multiparametric MRI are helping clinicians move beyond indirect markers toward a more complete, data-driven understanding of metabolic health.

If you’re attending, connect with our team on the ground at Booth 417!

🗓️ Book a meeting with us: https://t8glx.share.hsforms.com/2pZ-uQnvBQ562gUAkYToz9Q

08/04/2026

We’re looking forward to connecting at the American Association of Clinical Endocrinology meeting!

As a Gold Corporate Partner of AACE and an Industry Sponsor of the Annual Meeting, Perspectum is proud to be part of this collaborative forum, bringing together leaders across the endocrinology ecosystem to discuss shared priorities in advancing patient care.

We’re keen to exchange insights on the role of MR imaging in metabolic disease, explore opportunities for collaboration, and continue shaping the future of metabolic health together.

01/04/2026

Recognition is meaningful, but impact is what matters most.

Perspectum has been named in theThe Business Magazine - South East Thames Valley 250, highlighting leading businesses shaping the region’s future.

Over the past year, we’ve continued to advance how complex diseases are understood and managed, combining quantitative imaging with data-driven insight to support clinical decision-making, research, and more personalized care.

This recognition reflects the work of our teams and collaborators, and a shared commitment to enabling precision medicine in practice, not just in principle.

Learn more about our work: https://perspectum.com/

09/03/2026

Precision medicine must be precise for women.

This International Women’s Day, under the theme “Give to Gain,” we’re reflecting on what progress in women’s health truly requires: giving space to women’s data, giving weight to women’s symptoms, and giving clinicians better tools.

Because what we collectively gain is powerful:

• earlier answers
• clearer risk assessment
• better-informed monitoring over time

Conditions such as HFpEF, which is more common in women and frequently under-recognised, illustrate that cardiovascular risk is dynamic rather than static. Disease stage and severity significantly influence outcomes, with progression associated with substantially worse morbidity and mortality.

The analysis of UK Biobank data, presented by Dr Masliza Mahmod at ESC Congress 2025, highlighted how advancing HFpEF stage is associated with markedly increased risk of major adverse cardiovascular event, reinforcing the importance of earlier identification and more precise risk stratification.

At Perspectum, we’re advancing noninvasive, quantitative imaging that supports clinicians with objective insights, helping guide earlier identification, risk stratification, and monitoring over time.

Progress happens when research, technology, clinicians, and patients work in partnership. Today, we’re celebrating the women advancing healthcare in clinics, research, industry, and through lived experience, and recommitting to the shared effort needed to ensure women are seen, heard, and supported across the full spectrum of health.

05/03/2026

Not all weight loss is metabolically equal. And weight gain may be even more asymmetric.

Standing on the scale tells you how much weight changed.
It does not tell you where that change occurred. That distinction matters.

In a longitudinal study published in 's International Journal of Obesity, of approximately 3,000 UK Biobank participants with repeat abdominal MRI over 2.5 years, we quantified how fat and muscle compartments shift with natural weight change. These data were captured before widespread GLP-1 use.

Among individuals who lost 10–15% of body weight:
• Liver fat reduced by ~30%
• Visceral fat reduced by ~40%

In contrast, similar weight gain was associated with:
• ~70% increase in liver fat
• ~60% increase in visceral fat

Muscle behaved differently. It did not increase with weight gain and declined even with modest 2–5% weight loss. Intramuscular fat accumulated with weight gain and showed limited reduction, even at higher levels of weight loss.

The implication is clear: body weight alone is an incomplete endpoint.

As GLP-1 therapies drive unprecedented weight reduction, compartment-level imaging biomarkers will be critical for:
• Selecting meaningful clinical trial endpoints
• Accurately powering studies
• Understanding tissue-specific effects beyond BMI

This large-scale, pre-incretin reference dataset provides an objective baseline for interpreting metabolic change in the modern therapeutic era.

As Professor Lee Kaplan notes:
"GI hormone-based therapies are rapidly expanding effective treatment options for people with obesity and MASLD. This study of more than 3,000 adults from the general population uses MRI to quantify the impact of weight change on body composition and liver fat. The findings provide a real-world benchmark for what clinicians may expect from weight loss or gain, and an important reference point as we enter this new therapeutic era."

Read the full paper: https://www.nature.com/articles/s41366-026-02037-y

Address

Gemini One 5520 John Smith Drive
Oxford
OX42LL

Opening Hours

Monday	9am - 5pm
Tuesday	9am - 5pm
Wednesday	9am - 5pm
Thursday	9am - 5pm
Friday	9am - 5pm

Telephone

+44 (0)1865 655343

Website

http://www.perspectum.com/

Alerts

Be the first to know and let us send you an email when Perspectum posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Perspectum:

Shortcuts

Address
Telephone
Opening Hours
Alerts
Contact The Practice
Claim ownership or report listing

Want your practice to be the top-listed Clinic in Oxford?